Innate is planning to begin a Phase III confirmatory trial on lacutamab as it vies for the drug’s accelerated approval in a rare CTCL subset.

Innovent Biologics and Daiichi Sankyo have signed an exclusive agreement to commercialise Vanflyta, an oral type II FLT3 inhibitor, in China.

Alongside Alkeus, companies like Belite Bio, Ocugen and Nanoscope are aiming to secure a place on the Stargardt market with no approved drugs.

Eli Lilly has lifted its full-year outlook for the second time this year on the back of another strong quarter, indicating it is far from relinquishing its dominant position as pace setter on the ...

Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop treatments for fibro-inflammatory diseases.

Pfizer emerged as a pharmaceutical powerhouse during the pandemic, but lower infection rates and narrower use cases mean its Covid-19 brands are impacting the company’s bottom l ...

CapVest Partners-backed Curium has agreed to acquire rival US-based radiopharmaceutical company Lantheus in an all-cash deal worth up to nearly $8bn.

Evotec and Odyssey Therapeutics have announced a strategic AI-enabled R&D partnership to explore new treatments for autoimmune and inflammatory diseases.

The approval means mFlusiva becomes the first mRNA-based vaccine to be authorised on the US market for flu prevention.

Set against the backdrop of a mixed Q2, Novo Nordisk is eyeing bolt-ons in favour of transformative acquisitions.

Philadelphia-based biotech Context Therapeutics has terminated the development programme for one of its pipeline bispecific T-cell engagers (BiTEs) as the company looks to cut cos ...

GlobalData previously flagged Orzeyful’s approval in narcolepsy as a key Q3 catalyst for pharma due to the drug’s ‘transformative’ potential.